Related Experiment Video
Updated: Dec 7, 2025

07:28
Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation
Published on: October 11, 2024
596
Comparison of Patch Materials for Pulmonary Artery Reconstruction
Nicholas Ebert1, Michael McGinnis2, William Johnson3
1University of Minnesota Medical School, Minneapolis, Minnesota.
Seminars in Thoracic and Cardiovascular Surgery
|September 25, 2020
Summary
Patch material choice for pulmonary artery reconstruction does not impact reintervention rates. This finding, alongside significant cost variations, supports value-based decision-making in pediatric cardiac surgery.
Area of Science:
- Cardiovascular Surgery
- Pediatric Cardiac Surgery
- Biomaterials in Medicine
Background:
- Pulmonary artery reconstruction often involves various patch materials with differing costs.
- Informing value-based decisions requires understanding the relationship between patch material and reintervention rates.
Purpose of the Study:
- To analyze reintervention rates based on different patch materials used in pulmonary artery reconstruction.
- To evaluate if patch material type influences the need for subsequent interventions.
Main Methods:
- Retrospective review of 214 pulmonary artery reconstruction sites (2000-2014) at a single center.
- Exclusion of patients with unifocalization of aortopulmonary collaterals.
- Analysis of reintervention as the primary outcome, utilizing Cox proportional hazards regression.
Main Results:
- No significant relationship was found between the type of patch material (homograft, bovine pericardium, autologous pericardium, porcine submucosa) and reintervention rates (P=0.197).
- Preoperative renal failure (HR 4.36) and lower weight at surgery (HR 0.93) were associated with increased reintervention.
- Patch costs varied widely, from $0 for autologous pericardium to $6,105 for homograft branch patch.
Conclusions:
- Patch material type is not a determinant of reintervention for pulmonary artery reconstruction.
- Disparities in patch material costs, without impact on reintervention, can guide value-based healthcare decisions.
- Surgeons can prioritize cost-effectiveness without compromising clinical outcomes related to reintervention.

